Sakurako Oyama

Objectives Recent studies suggest that early menarche may increase cardiometabolic morbidity and mortality. Yet few studies have examined this association in the Pacific Islands, where obesity prevalence is among the highest globally. We sought to examine associations between age at menarche and cardiometabolic risk in Samoa. Methods Participants were from the Soifua Manuia study ( n = 285, age 32–72 years) conducted in Samoa from 2017 to 2019. Logistic regressions were conducted to estimate odds of obesity, hypertension, diabetes, dyslipidemia, and metabolic syndrome per one‐year increase in age at menarche. Linear regressions were conducted to examine associations between age at menarche and continuous measures of adiposity, blood pressure, insulin resistance, and serum lipids. Results Median age at menarche was 14 years (IQR = 2). After controlling for relevant covariates, each one‐year increase in age at menarche was associated with a 15% decrease (OR = 0.85, 95% CI: 0.72–1.01, p = .067) in odds of hypertension, but a 21% increase (OR = 1.21, 95% CI: 1.01–1.45, p = .044) in odds of diabetes and 18% increase (OR = 1.18, 95% CI: 0.98–1.42, p = .081) in odds of high total cholesterol. Each additional year in age at menarche was associated with a 1.60 ± 0.52 kg ( p = .002) decrease in lean mass and 1.56 ± 0.51 kg ( p = .003) decrease in fat‐free mass. Conclusions Associations between age at menarche and cardiometabolic risk may be population‐specific and are likely influenced by both current and historical nutritional and epidemiological contexts. Prospective studies are needed to clarify the role of childhood adiposity and other early life exposures on age at menarche and subsequent cardiometabolic risk.